6 June 2019 in News

How to generate high-quality, alignable sequence data?

Innovation Alert: Mid-read sequencing Sequencing of PE250 reads on the NovaSeq 6000   Printing a book of more than 2 billion pages, every two days. Illumina’s NovaSeq 6000 has made…

Read More
4 June 2019 in News

GenomeScan to offer two Bioinformatics PhD traineeships as part of the EU Horizon 2020 program

Two EU-funded Consortium Grants for PhD training at GenomeScan GenomeScan has been granted two Marie Skłodowska-Curie Actions within the Innovative Training Network calls of the European Union-funded Horizon 2020 Program….

Read More
29 May 2019 in Blog

Some highlights from SMRT Meeting, Leiden, May 2019

Some highlights from SMRT Leiden 2019 Innovation in long-read sequencing applications SMRT Leiden – 7th -9th of May 2019 Arnoud Schmitz – PacBio® expert at GenomeScan The yearly PacBio meeting…

Read More
23 May 2019 in Science article

Widespread and Functional RNA Circularizationin Localized Prostate Cancer.

Widespread and Functional RNA Circularizationin Localized Prostate Cancer Sujun Chen, Vincent Huang, Xin Xu, Julie Livingstone, Fraser Soares, Jouhyun Jeon, Yong Zeng, Junjie Tony Hua, Jessica Petricca, Haiyang Guo, Miranda…

Read More

How to generate high-quality, alignable sequence data?

By | News | No Comments

Innovation Alert: Mid-read sequencing

Sequencing of PE250 reads on the NovaSeq 6000

 

PE250 reads fig.1 Blog

Printing a book of more than 2 billion pages, every two days. Illumina’s NovaSeq 6000 has made it possible to
produce >6 Terabases of high-quality bases per sequencing run. This huge amount keeps the cost per base low and has allowed for the development of many new applications.

With such a complete solution, what is the drawback? Usually none; but to resolve certain research questions, 150 nucleotide (nt) sequencing is not sufficient. Some cases require generating fragments up to 250 nt to uniquely map most of the reads.

PE250 reads fig.2 Blog

Now, GenomeScan offers PE250 sequencing under ISO/IEC 17025 accreditation. Longer reads can, for example, span the highly variable regions in T-cell or B-cell receptors (TCR, BCR). Or they form ‘larger puzzle pieces’, to resolve repetitive regions. This can be beneficial for resequencing of whole genomes or microbiome sequencing.

What is the quality of those longer runs?
As is shown in the figure above, the quality stays very high during the run and produces reads that are of superior quality (high % of Q30 reads). With PE250 sequencing on the NovaSeq, GenomeScan can offer cost-effective sequencing of up to 500 nt.PE250 Tab.1 1024x161 Blog

PE250 reads fig.3 1024x296 Blog

Do you have questions or want to know how NGS could benefit your project? Just leave your message below and André will contact you…

 

 

GenomeScan to offer two Bioinformatics PhD traineeships as part of the EU Horizon 2020 program

By | News | No Comments

logo Blog Two EU-funded Consortium Grants for PhD training at GenomeScan

GenomeScan has been granted two Marie Skłodowska-Curie Actions within the Innovative Training Network calls of the European Union-funded Horizon 2020 Program. These PhD traineeships are part of Horizon 2020 Grants acquired by two different Consortia where Academia and Industry collaborate closely together. Recruitment of PhD candidates with a focus on Bioinformatics will start near the end of 2019 (applications are welcome as of today).

The proEVLifeCycle Project (ID 860303) aims to study the life cycle of extracellular vesicles in prostate cancer – from biogenesis and homing, to functional relevance. Prostate cancer presents as a major health care problem for men, with EU-wide approximately 365,000 new cases annually (reference https://ec.europa.eu/jrc/en/publication/epidemiology-prostate-cancer-europe). Current means to identify rapid from slow progressing tumors are lacking specificity. There is an unmet need to means of non-invasive discrimination of these tumors and identification of novel targets for therapeutic intervention of high-risk tumors. The proEVLifeCycle Project will aid to the understanding of prostate cancer progression and consequently, to the implementation of novel biomarkers and therapeutic interventions to have a lasting impact on this indiscriminate and lethal disease.

The goal of the TrainCDKis Project (ID 860977) is to provide a multidisciplinary training programme to top-level young scientists to develop creative solutions for chronic kidney disease – from genetic modifiers to drug discovery. Chronic kidney disease is characterized by the progressive decline of renal function, associated with impaired quality of life and reduced life expectancy. It affects 10-15% of the worldwide population and is recognized as an increasing global health problem with a substantial burden on health-care budgets. The research projects within TrainCKDis will address key challenges focusing at genetic and epigenetic modifiers able of identifying patients that are predisposed to disease progression, biomarkers for disease monitoring and identification of novel therapeutic targets to impact the limited treatment options.

Fotos GenomeScan to offer two Bioinformatics PhD traineeships Post Blog